What question did this study set out to answer?

To evaluate the long-term outcomes of durvalumab following chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

February 8, 2026Open Access

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

NGN. GirardUniversité de Versailles Saint-Quentin-en-Yvelines JBJ. BarSheba Medical Center PBP. BaasLeiden University Medical Center

Puntos clave

To evaluate the long-term outcomes of durvalumab following chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
Analysis of mature data from the PACIFIC-R cohort
Focus on overall survival (OS) and real-world progression-free survival (rwPFS)
Assessment of durvalumab as a consolidation therapy
Durvalumab shows improved overall survival in the cohort
Real-world progression-free survival supports effective treatment outcomes
Findings advocate for durvalumab as standard of care in this patient population

Resumen

PACIFIC-R provides mature data on OS and rwPFS from a large, real-world cohort, supporting consolidation durvalumab as a standard of care in this setting.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo